Changes and trends in medication-assisted treatment in Israel.
Medication assisted treatment
Opioid agonist therapy
Opioid maintenance treatment
Opioid use disorder
Journal
Israel journal of health policy research
ISSN: 2045-4015
Titre abrégé: Isr J Health Policy Res
Pays: England
ID NLM: 101584158
Informations de publication
Date de publication:
26 01 2023
26 01 2023
Historique:
received:
18
01
2022
accepted:
27
12
2022
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
28
1
2023
Statut:
epublish
Résumé
As opioid prescription in Israel is increasing, there is a growing need for monitoring opioid use disorder and providing opioid agonist therapy. Our goal is to describe, sub-analyze, and identify obstacles in the treatment of opioid misuse in the Israeli medication assisted treatment centers. Data on methadone, buprenorphine, and buprenorphine combined with naloxone for the indication of opioid addiction treatment for the period 2013-2020 were obtained from pharmaceutical companies that distribute them in Israel. Data on utilization of these drugs were also extracted from the database maintained by the Israel Ministry of Health's Pharmaceutical Administration Division. The data were converted to defined daily doses (DDD)/1000 inhabitants/day. The number of patients receiving medication assisted treatment increased by 10% since 2013, with a shift from buprenorphine alone to buprenorphine/naloxone in government-run centers. Methadone remains the most popular maintenance drug. The change in opioid maintenance prescription does not match the significant increase in opioid consumption. Optimization of treatment can be achieved by the creation of a comprehensive database, cooperation between healthcare organizations and the government and further development of non-stigmatic and accessible services.
Sections du résumé
BACKGROUND
As opioid prescription in Israel is increasing, there is a growing need for monitoring opioid use disorder and providing opioid agonist therapy. Our goal is to describe, sub-analyze, and identify obstacles in the treatment of opioid misuse in the Israeli medication assisted treatment centers.
METHODS
Data on methadone, buprenorphine, and buprenorphine combined with naloxone for the indication of opioid addiction treatment for the period 2013-2020 were obtained from pharmaceutical companies that distribute them in Israel. Data on utilization of these drugs were also extracted from the database maintained by the Israel Ministry of Health's Pharmaceutical Administration Division. The data were converted to defined daily doses (DDD)/1000 inhabitants/day.
RESULTS
The number of patients receiving medication assisted treatment increased by 10% since 2013, with a shift from buprenorphine alone to buprenorphine/naloxone in government-run centers. Methadone remains the most popular maintenance drug.
CONCLUSIONS
The change in opioid maintenance prescription does not match the significant increase in opioid consumption. Optimization of treatment can be achieved by the creation of a comprehensive database, cooperation between healthcare organizations and the government and further development of non-stigmatic and accessible services.
Identifiants
pubmed: 36698178
doi: 10.1186/s13584-022-00551-8
pii: 10.1186/s13584-022-00551-8
pmc: PMC9876650
doi:
Substances chimiques
Analgesics, Opioid
0
Buprenorphine
40D3SCR4GZ
Methadone
UC6VBE7V1Z
Naloxone
36B82AMQ7N
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1Informations de copyright
© 2023. The Author(s).
Références
Clin J Pain. 2010 Nov-Dec;26(9):770-6
pubmed: 20842012
MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):349-358
pubmed: 29596405
Eur Addict Res. 2017;23(6):276-283
pubmed: 29268270
N Engl J Med. 2022 Aug 25;387(8):672-675
pubmed: 35984354
MMWR Morb Mortal Wkly Rep. 2018 Jan 04;67(5152):1419-1427
pubmed: 30605448
Addict Sci Clin Pract. 2021 Mar 17;16(1):19
pubmed: 33731210
Drug Alcohol Depend. 2018 Apr 1;185:112-119
pubmed: 29432974
Pain Med. 2009 May-Jun;10(4):702-7
pubmed: 19453956
J Addict Med. 2020 Mar/Apr;14(2S Suppl 1):1-91
pubmed: 32511106
Int J Drug Policy. 2022 Jan;99:103472
pubmed: 34649203
J Neurosci Rural Pract. 2012 Jan;3(1):45-50
pubmed: 22346191
Addiction. 2007 Feb;102(2):289-300
pubmed: 17222284
JAMA Netw Open. 2021 Sep 1;4(9):e2125538
pubmed: 34533569
Cureus. 2021 Sep 16;13(9):e18012
pubmed: 34667687
J Electrocardiol. 2013 Nov-Dec;46(6):519-23
pubmed: 24035102
Pharmacoepidemiol Drug Saf. 2018 May;27(5):535-540
pubmed: 29488288
JAMA Psychiatry. 2019 Feb 1;76(2):208-216
pubmed: 30516809
Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207
pubmed: 24500948
Drug Alcohol Depend. 2021 Nov 1;228:109028
pubmed: 34500239
Isr J Health Policy Res. 2019 Oct 16;8(1):75
pubmed: 31619286
Eur J Clin Pharmacol. 2011 Feb;67(2):165-8
pubmed: 21057940